RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-07

Study Completion Date

2020-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Post-operative cystoid macular oedema (CMO) is a common complication causing visual loss following routine cataract surgery. This complication is more prevalent in eyes with excessive inflammation as they heal from surgery.

Prostaglandin analogues (PGA) are the commonest first line drugs used in the long-term treatment of primary open angle glaucoma (POAG)- where they reduce the pathologically high pressure in the eye. Prostaglandins are inflammatory mediators.

In the post-operative care of glaucoma patients undergoing cataract surgery, there is a clinical dilemma whether to stop or continue the use of prostaglandin eye drops. Clinical practice is completely dichotomized between continuing and stopping PGA treatment in the postoperative period. There is conflicting scientific literature on the effect of PGA on the incidence of CMO; and only a single randomized control trial (Miyake K, Arch Ophthalmol 1999, 117:34-40), where the post operative regime is not applicable to present practice, compared the incidence of CMO following routine cataract surgery in POAG on PGA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prednisolone Acetate Eye Drops for Pain Intervention in Second Eye Cataract Surgery

NCT06614348

NOT_YET_RECRUITING PHASE2

The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma

NCT02388360

Glaucoma, Open-Angle

COMPLETED PHASE4

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification

NCT01021761

Cataracts

COMPLETED PHASE4

Study for Optimizing Anti-inflammatory Prophylaxis

NCT03383328

Postoperative Cystoid Macular Edema Irvine-Gass Syndrome

COMPLETED PHASE4

PGE2 Levels in Patient Treated With NSAIDs

NCT03597867

Ocular Inflammation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims to answer the common clinical question of whether or not to stop PGA after routine cataract surgery. Cataract surgery is the commonest operation performed on the NHS and the prevalence of glaucoma is 5% in the population over 80 years old. Thus the clinical dilemma is a common one.

A current literature search reveals that a divided opinion over whether PGAs do increase the incidence of CMO. No study has yet established a causal relationship between the use of PGAs and the development of CMO. Anecdotal reports and small case series have associated peri-operative PGA use with the occurrence of CMO (Henderson BA et al, 2007 J Cataract Refract Surg 33:1550-1558; Moroi SE et al, 1999, Ophthalmology 106:1024-1029). Whilst, in direct contrast, other authors argue CMO as a rare phenomenon and the causative relationship is debated (Schumer RA et al 2000, Curr Opin Ophthalmol 11:94-100; Miyake K et al 2003 J Cataract Refract Surg 29:1800-1810)

The most similar previous study to the one proposed, was by Miyake K et al. (Arch Ophthalmol 1999, 117:34-40). The key difference, though, is in the postoperative drop regime of fluorometholone and diclofenac in that paper and current UK clinical practice of using dexamethasone. In terms of study design, this paper used an invasive method of investigating CMO by fundus fluorescein angiography compared to OCT proposed here.

A recent case report by Agange N \& Mosaed S (Journal of Ophthalmology, 2010) concludes with 'conclusions about causal relationships cannot be made without well-designed, prospective clinical trials addressing this issue'.

This study will therefore use drops that are routinely used in current UK clinical practice and add to the body of evidence that helps answer the question should PGAs be continued after cataract surgery so as to prevent the progression of glaucoma in patients.

* Aim

* This study investigates if the occurrence of CMO after cataract surgery is affected by the use of PGA drops by patients with glaucoma
* The null hypothesis states there is no increase in the incidence of CMO on OCT scanning in the 4 weeks following cataract surgery whether PGA eye drops continue or are stopped.
* Design

* Randomised control study with parallel group design
* Single masking of outcome assessors

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open Angle Glaucoma and Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomised Control Trial

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

* The patient is not masked as to treatment group and are aware of whether they are to continue or stop the PGA drops
* The care providers are not masked as to treatment group
* Outcome assessors are masked as to the patient's treatment group for their analysis of the OCT scans over the 4 week peri-operative period.

* The scans are recorded with only the randomised identifier.
* This is to reduce bias in the analysis of the scans
* Unmasking of each patient will occur after their analysis of their week 4 OCT scan

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stop prostaglandin eye drops post op

Stop prostaglandin eye drops post operatively. Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost

Group Type OTHER

Prostaglandins

Intervention Type DRUG

Continue prostaglandin eye drops post op

Continue prostaglandin eye drops post operatively Prostaglandins either stopped or continued after cataract surgery. Latanoprost Travaprost Bimatoprost Tafluprost

Group Type OTHER

Prostaglandins

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prostaglandins

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Latanoprost Travaprost Bimatoprost Tafluprost

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary open-angle glaucoma and ocular hypertensive subjects undergoing cataract surgery (routine phacoemulsification and intraocular lens implantation) AND on current topical glaucoma treatment with a prostaglandin analogue eye drop for at least 2 months prior to cataract surgery.
* Subjects capable of giving informed consent

Exclusion Criteria

* Subjects with additional risk factors for macula oedema (eg. diabetic retinopathy, previous macula oedema, uveitis)
* Subjects with advanced glaucoma

* Advanced visual field loss (Humphrey Mean Deviation \>-12dB)
* Advanced glaucomatous disc changes (vertical cup-to-disc ratio \>0.9)
* Subjects with non-controlled intraocular pressure (IOP) (pre-operative IOP \>22 mmHg)
* Any contra-indication to the use of topical prostaglandin drops
* Any contra-indication to the use of routine post-operative dexamethasone 0.1% eye drops
* Pregnancy
* Patients unable to give informed consent
* Intra-operative complication during cataract phacoemulsification and intraocular lens implantation

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No